Evidence map›Paper›PMID 36555257›Full record

ArticleInternational journal of molecular sciences2022

Zingerone Attenuates Carfilzomib-Induced Cardiotoxicity in Rats through Oxidative Stress and Inflammatory Cytokine Network.

Mohammad Firoz Alam, Sami I Hijri, Saeed Alshahrani, Saad S Alqahtani, Abdulmajeed M Jali, Rayan A Ahmed, Mansour M Adawi, Sameeh M Algassmi, Emad Sayed Shaheen, Sivakumar S Moni and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Carfilzomib-induced severe pulmonary interstitial injury.Irish journal of medical science · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Mohammad Firoz AlamDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-4716-8658
Sami I HijriDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.
Saeed AlshahraniDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-9626-219X
Saad S AlqahtaniDepartment of Pharmacy Practice, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-6164-9095
Abdulmajeed M JaliDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-8844-2385
Rayan A AhmedDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-8675-1264
Mansour M AdawiDepartment of Histopathology, King Fahad Hospital, Jazan 45142, Saudi Arabia.
Sameeh M AlgassmiDepartment of Histopathology, King Fahad Hospital, Jazan 45142, Saudi Arabia.
Emad Sayed ShaheenDepartment of Animal House, Medical Research Centre, Jazan University, Jazan 45142, Saudi Arabia.
Sivakumar S MoniDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-4860-0166
Tarique AnwerDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-3211-1886
Jazan University · SAKing Fahad Central Hospital · SA

Funding

Saudi Arabian Ministry of Education's Deputyship for Research and Innovation Support, Saudi Arabia. RUP20-01
6 · The paper itself

Abstract

Carfilzomib (CFZ) is an anticancer medication acting as a selective proteasome inhibitor. However, it can cause cardiovascular problems, increasing mortality and morbidity. This study aimed to investigate whether zingerone (ZRN) could help reduce carfilzomib-induced cardiotoxicity in Wistar albino rats. Rats were divided into five groups of six animals each. The first group received normal saline as a control (NC); the second group received multiple doses (six) of CFZ (4 mg/kg) intraperitoneally (IP); the third and fourth groups received zingerone (50 mg/kg and 100 mg/kg oral) along with six doses of CFZ for 16 days; and the fifth group received only 100 mg/kg zingerone orally. Hematological, biochemical, oxidative stress, and histopathological studies confirmed the findings of CFZ-induced cardiotoxicity. We found that ZRN significantly attenuated the effects of CFZ on oxidative stress by enhancing the antioxidant properties of glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD). Additionally, ZRN reduces inflammatory cytokines and apoptotic markers, such as IL-1β, IL-6, TNFα, and caspase-3. Overall, zingerone prevents carfilzomib-induced cardiotoxicity in rats, as evidenced by histopathological studies.

Indexed as

CardiotoxicityCytokinesAnimalsAntioxidantsGlutathioneGuaiacolOligopeptidesOxidative StressRatsRats, WistarAntioxidantscarfilzomibCytokinesGlutathioneGuaiacolOligopeptideszingeroneapoptosiscardiotoxicity histopathologycarfilzomibcytokinesoxidative stresszingerone

Identifiers

PMID36555257
PMCPMC9779556
OpenAlexW4311979732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.